Sunho Biologics, Inc. (SEHK: 2898)
Health Care · Biotechnology · CN
HK$—
— today · — 1Y
Sunho Biologics, Inc. (SEHK: 2898) operates in the Biotechnology industry within the Health Care sector. The company is valued at $123.78M and employs 130 people.
trading between 3.99 and 8.60.
Tweenvest scores Sunho Biologics, Inc. across four factors: quality 26/100. Its strongest factor is quality.
2898 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $123.78M
- Revenue (TTM)
- $2.37K
- P/E
- —
- EPS
- -0.54
- Dividend yield
- —
- Beta (5Y)
- 0.44
- 52-week high
- HK$8.60
- 52-week low
- HK$3.99
- Avg volume (3M)
- —
- Shares outstanding
- 151.87M
- Employees
- 130
- Next earnings
- —
About Sunho Biologics, Inc.
Sunho Biologics, Inc. is a biopharmaceutical firm dedicated to discovering, advancing, and bringing to market biological therapies. These treatments are designed to influence the body's immune system, both its inherent and adaptive responses, thereby altering the immune microenvironment. Among its portfolio is IAH0968, a monoclonal antibody specifically engineered to enhance antibody-dependent cell-mediated cytotoxicity, currently undergoing Phase II clinical trials for the treatment of biliary tract carcinoma and colorectal cancer. The company also develops IAP0971 and IAE0972, a pair of immunocytokines that have successfully concluded Phase I clinical trials for various advanced solid tumors, notably non-small cell lung cancer and colorectal cancer. Sunho Biologics also boasts a robust pipeline of early-stage assets. These include IBB0979, an immunocytokine targeting solid tumors; IBC0966, a dual-action fusion protein (anti-PD-L1 antibody-signal regulatory protein) in clinical development, designed to elicit tumor-specific immune responses; IBD0333, aimed at tumor cells; IAN0982, another oncology candidate; and immunosuppressants ISH0988 and ISH0613, which are being explored for autoimmune conditions. Established in 2018, the company operates from its headquarters in Huzhou, China, and functions as a subsidiary of Sunho Wisdom Investments Limited.
- ISIN
- KYG8572S1021
- Founded
- 2018
- Listed since
- Sep 5, 2002
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €874.20 | +1.16% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $141.83 | +2.12% |
Figures last refreshed Aug 18, 2026.